At the end of April 2021, the most astonishing news broke out in the CKD community. This was the biggest news toward a new treatment for chronic kidney disease in more than 20 years. The US Food and Drug Administration (FDA) approved AstraZeneca’s Farxiga (dapagliflozin) as a treatment for CKD in patients at risk of further progression with and without type-2 diabetes. 

 

During the DAPA-CKD Phase III trial, the oral, once-daily sodium-glucose cotransporter 2 inhibitor revealed a remarkable drop in the risk of worsening of renal function, end-stage kidney disease (ESKD), and risk of cardiovascular or renal death versus placebo in stage 2-4 CKD patients with high urinary albumin excretion. 

 

Farxiga by AstraZeneca was first approved in 2014 to improve glycemic control in adults with type 2 diabetes. During this trial, 4304 patients were randomly given either Farxiga or a placebo. The trial suggested a 39% decline in the risk of declining renal function, cardiovascular death, as compared to a placebo in stage 2 to 4 CKD patients with high urinary albumin excretion.

 

Why Is Creatinine So Important For Chronic Kidney Disease Treatment?

Innovations In Kidney Disease Treatment

For more of the latest information on ways to achieve good kidney health, head over to our YouTube Channel